Emerging Opportunities in Myanmar's Diagnostic Imaging and In-Vitro Diagnostics

Myanmar’s
Diagnostic Imaging &
In-vitro Diagnostics
Solidiance has produced this white paper for information purposes only. While every effort has been made to ensure the accuracy of the information
and data contained herein, Solidiance bears no responsibility for any possible errors and omissions. All information, views, and advice are given in
good faith but without any legal responsibility; the information contained should not be regarded as a substitute for legal and/or commercial advice.
Copyright restrictions (including those of third parties) are to be observed.
DECEMBER 2015
Emerging Opportunities in
solidiance

2 | www.solidiance.com
executive summary Myanmar’s Healthcare economics
3 4
15 Diagnostic Imaging (DI) in Myanmar: market potentials
21
28
29
33
34
37
In-vitro Diagnostics (IVD) in Myanmar: market challenges
Registration & licensing of Diagnostic Imaging (DI) and
In-vitro diagnostic (IVD) equipment
Case studies
key takeaways
INFOGRAPHIC
ABOUT US
CONTENT

www.solidiance.com | 3
Economic growth and demographic changes in Myanmar are driving healthcare
spending throughout the country. Myanmar’s total healthcare expenditure is set to
cross USD 2 billion for FY 2015-2016.
Rapid growth in healthcare demand is inevitably resulting in the development of the
healthcare system. There is also growing awareness of regular health check-ups for
early detection of non-communicable diseases.
Diagnostic Imaging & In-Vitro Diagnostics have witnessed quick penetration into
Myanmar since 2012. However, demand is increasing faster than supply and global
healthcare players need to adapt to a fast evolving market. Myanmar presents a set
of unique growth opportunities for global healthcare players and a sustainable long-
term strategy is required to capitalize on these opportunities.
executive
summary

Myanmar’s
Healthcare
economics

Percentage of contribution from government
to total healthcare expenditure has grown from
12% in 2010 to 40% in 2014
• 2.7% of total government budget was allocated to healthcare in 2014
• Government proposed a plan in parliament in January 2015 to increase healthcare budget allocation with an
annual growth rate of 6% until 2020
619
790
922
1,041
1,146
85
118
456
572
757
2010 2011 2012 2013 2014
Private Spending Public Spending
908
1,378
704
1,613
1,903
27.5
13.04
1.9
14.1
17.2
11.16
Myanmar’s Total Healthcare Expenditure Split
(USD Mn)
Source: World Health Organization (WHO), Ministry of Health (MOH), Solidiance Research and Analysis
Comparison of Total Healthcare
Expenditure in USD Bn (2014)

Myanmar has the lowest
healthcare spending in
Southeast Asia
3.1%
4.0%
4.6% 4.6%
6.0%
2.7%
• Around 70% of Myanmar’s population stay in rural
areas with minimal access to healthcare services that
are primarily concentrated in the big cities: Yangon,
Mandalay, and Nay Pyi Taw
• Majority of the increase in healthcare expenditure is
targeted to tier-2 cities
107
423
35
2,507
264
111
Myanmar’s Healthcare Expenditure
(% of GDP) – 2014
Comparison of Per Capita Total
Healthcare Expenditure (USD) – 2014
Indonesia
Malaysia
Myanmar
Singapore
Thailand
Vietnam
Source: Solidiance Research & Analysis, WHO, MOH

Out-of-pocket (OOP) expenses are mainly used for self-prescribed
medicine, diagnostics and private clinics.
Public hospitals are subsidizing costs of diagnostics and providing
medicine for the most needed people.
Under the Social Security Scheme, all employers and employees
who contribute to the scheme are entitled to healthcare benefits
and treatment in certain hospitals which are listed by Social Security
Board.
International NGOs (INGO) are financially supporting to strengthen
primary healthcare services and facilities in rural areas.
In July 2015, the Myanmar government approved to sell “Health
Insurance” to the public through Myanmar’s Insurance and 12 private
insurance companies.
• Cost of one health insurance unit is MMK 50,000, or
approximately USD 45 – and a person can buy up to 5 units
• The coverage of healthcare expenses for one unit of health
insurance is mainly for hospitalization expenses, which is MMK
15,000 per day for five times in 30-day period of hospitalization
(up to 150 days)
Out-of-pocket payment
is the key dominant source
for healthcare financing,
accounting for 78% of the
total healthcare expenditure
in Myanmar
OOP
Public & Government
Hospitals
INGO
Social Security
Scheme
78%
15%
6%
1%
Myanmar’s Health expenditure
by financing agents, 2014
Myanmar’s new health insurance scheme
Source: Ministry of Health (MOH), Solidiance Interviews and Analysis

Effects of increased government
spending in the last 2 years can be seen
in the public hospitals in Myanmar’s
tier 2 & tier 3 cities
69%
7%
3%
3%
2%
14%
1%
Public Primary Care Hospitals
Public Secondary Care Hospitals
Public Tertiary care Hospitals
Military Hospitals
Government's Ministry Hospitals
Private General Hospitals
Traditional Medicine Hospitals
Myanmar’s Type of Hospitals by
level, 2014 (1,192 hospitals)
Source: WHO, Health System Review 2014 Report from MOH, Solidiance Research and Analysis

93%
7%
Public sector
Private sector
Hospital Beds in
Myanmar by sector,
2014 (73,040 beds)
Public tertiary care hospitals are catering to
specialized medical treatments and services
in big cities like Yangon, Mandalay, Nay Pyi
Taw, and Taunggyi.
The Ministries of Railways, Labour, Mines,
Industry, Energy & Cooperatives as well as
Home Affairs are providing medical care
and treatment to their employees through
their own run hospitals.
The majority of hospitals are providing basic
x-ray and ultrasound services.Source: WHO, Health System Review 2014 Report, MOH, Solidiance Research and Analysis

Private hospitals
account for 14%
of total hospitals
and contribute to
7% of total beds
in Myanmar
850
1,000
1,184
1,025
950
316
135
167
Public Hospitals Private Hospitals
Public hospitals account for ~86% of
hospitals but are far behind regional quality
standards.
In public hospitals, selected medicines and
lab tests are being offered for free to the
less fortunate since in the late 2014.
Private hospitals have increased in number
by 10% between 2011 and 2014.
Source: Central Statistical Organization, MOH, Myanmar
Private Hospitals’ Association, Solidiance Research &
Analysis
Number of hospitals in Myanmar - 2014

0 20 40 60 80 100 120 140 160
Shan State
Sagaing Region
Yangon Region
Mandalay Region
Bago Region
Ayeyawady Region
Magway Region
Kachin State
Rakhine State
Mon State
Taninthayi Region
Kayin State
Nay Pyi Taw
Chin State
Kayah State
Public Hospitals
Private Hospitals
Myanmar’s Private and Public
hospital distribution across the
country, 2014
Source: Central Statistical Organization, MOH, Myanmar Private Hospitals Association, Solidiance Research & Analysis

Half of the private hospitals in
Yangon have less than 25 beds
32%
15%
4%
50% >200
100-200
25-100
<25
Yangon hospitals by
number of beds, 2014
Number of beds Number of hospitals
<25 25
25-99 20
100-200 4
>200 3
Total 52
# Name of the Hospital # of beds
1 Pinlon 300
2 Asia Royal 232
3 Shwe Gon Dine Specialist Centre (SSC) 200
4 Sakura 150
5 Bahosi 120
6 Pun Hlaing 100
7 Witoriya 100
8 Aung Yadanar 70
9 Ma Har Mying 70
10 Parami 65
11 Green Cross Specialist 50
12 Thu Kha Kabar 50
13 Shin Par Ku 49
14 Academy 40
15 Thiri Sandar 38
16 Shwe La Min 34
17 Rose Hill 30
18 Kaung 25
19 Aye Myittar 25
20 Aye Myittar (Baby Clinics) 25
21 Aye Yeik Thar 25
22 Kant Kaw Diagnostic & Neuro Centre 25
23 Kaung Myat Mon 25
24 Myat Tar 25
25 Royal 25
26 Shwe Baho 25
27 Win 25
Advanced diagnostic tests are only offered in large hospitals (>100 beds)
List of hospitals with ≥ 25 beds in Yangon, 2014
Source: Solidiance Research & Analysis, Central Statistical Organization, Ministry of Health, Myanmar Private Hospitals Association

Most of the private hospitals in
Mandalay and Nay Pyi Taw have
less than 25 beds
List of hospitals with ≥ 25 beds in Mandalay in 2014
Mandalay Hospitals by no. of beds, 2014
Nay Pyi Taw Hospitals by no. of beds, 2014
List of hospitals with ≥ 25 beds in Mandalay in 2014
1 Nyein 120
2 City 100
3 Kant Kaw 80
4 Mandalar 55
5 Myat Thu Kha 50
6 Thit Sar 45
7 Ar Yaw Jan 25
8 Aye Thiri 25
9 Chan Nyein Aung 25
10 Hans 25
1 Outara Thiri 250
2 Bawga Theiddhi 40
3 Kaung Thit 25
50%
2,8%
8,34%14,58%
100 - 300 25 - 99 <25
1,14%
2,29%4,57%
100 - 300 25 - 99 <25
Source: Solidiance Research & Analysis, Central Statistical Organization,
Ministry of Health, Myanmar Private Hospitals Association

Number of death by non-communicable
diseases (NCD) has increased by 7%
between 2010 & 2014 in Myanmar
125.3
45.8
27
8.7
35.7
110.25
48.51
39.69
13.23
48.51
CVD Cancers Respiratory
diseases
Diabetes Other NCD
2010 2014
242.5 260.2
368
181
2010 2014
Other deaths
Non-communicable diseases
nuMBer of deaTH By non-coMMunicaBle diseases IN MYANMAR
(in THousand)Nmbthbth
nuMBer of deaTH By
causes IN MYANMAR
(in THousand)
Proportion of deaths by NCD has
increased from 40% in 2010 to 59% in
2014.
Increasing trend of chronic diseases
suggests severe need for better
diagnostic services.
The government has developed a
comprehensive national policy for
prevention and control of major NCDs.
Priority is given to early detection of
major NCDs by upgrading and installing
advanced medical devices to address
burden of premature deaths.
Source: National Statistical Office, Solidiance Research
& Analysis

Diagnostic
Imaging (DI)
in Myanmar:
market
potentials

Number of Diagnostic Imaging (DI) tests
conducted in Myanmar’s private facilities has
seen a big forward jump since 2012
• Basic diagnostic imaging tests such as x-ray & ultrasound are free in public hospitals for in-patients
• Military hospitals have advanced devices but these are primarily for military personnel and their families
• Patients in Yangon prefer to take diagnostic imaging tests in private hospitals due to 24-hour service
availability and better accuracy of results
• Basic diagnostic imaging tests such as X-ray and Ultrasound can be done in private diagnostic clinics
• In public hospitals, advanced diagnostic imaging devices like MRI & CT are only installed in large specialty
hospitals in major cities
Myanmar’s share of Diagnostic
Imaging tests by facilities in 2014
Source: Solidiance Interviews & Analysis
45%
24%
20%
11%
Public hospitals
Private hospitals
Military hospitals
Private diagnostic clinics

Increasing
awareness about
NCD has resulted
in increasing
demand for DI in
Myanmar
NCDs are identified as the major cause of
mortality - accounting for around 60% of
total death in 2014.
Estimated 60,000 cancer cases are
identified each year in Myanmar. Breast
cancer at 17%, is the most common cancer
in women while lung cancer is the common
in men.
Majority of deaths by NCD are due to non-
detection in early stages which is directly
related to diagnostic imaging.
Mortality rate by type
in Myanmar (2014)
Top cancer cases in
Myanmar (2014)
Source: Central Statistical Organization, WHO, Solidiance
Interviews & Analysis
Communicable maternal, perinatal
and nutritional conditions,
Cardiovascular diseases
Cancer
Other NCDs
Injuries
Chronic respiratory diseases
Diabetes
30%
25%
11%
11%
11%
9%
3%
38%
17%
16%
15%
5%
5%
4%
Breast
Lung, Bronchus, Trachea
Cervix Uteri
Stomach
Non Hodgkin's lymphoma
Oesophagus
Others

Victoria Hospital, one of the big private hospitals in
Myanmar, offers all diagnostic imaging tests
Advanced DI equipment is only available
in public tertiary hospitals and big private
hospitals in main cities like Yangon,
Mandalay, Nay Pyi Taw, and Taung Gyi
Thailand
X-ray
Myanmar
1,474
941
1,198
800
692
52
157
12
Ultrasound
CT
MRI
Number of installed machines in Myanmar, 2015
Most public hospitals are equipped with 2D Ultrasound machines
while 3D, 4D & Doppler machines are mostly found in private
hospitals.
30 CT scanners were added to public hospitals in 2013 – most of
which were second-hand machines from Japan & Singapore.
MRI scanners are only available at five public hospitals and seven
private hospitals in Myanmar.

Name of the Hospital
Public
hospitals
Military
hospitals
Private
hospitals
Private diagnostic
clinics
X-ray
3D/4D Ultrasound
CT -
MRI -
Radiation Therapy -
Bone Scan/Dexa Scan
Mammo
ECG/Echo Scan
Color-Doppler
Radiography (Radio/Fluoro)
Trans-Vg (TVS)
Fibroscan
Comparison of key Diagnostic Imaging (DI)
modalities in Myanmar
Source: Solidiance Research & Analysis, Ministry of Health, Myanmar Private Hospitals Association

Radiologist, Asia Royal Hospital
At Myanmar’s public hospitals, diagnostic
imaging tests are free for inpatients. Outpatients
still need to pay - but considerably cheaper than in
private facilities
Type of services Public Private/ Diagnostic Clinic
DI services
MRI scan USD 60 USD 190
CT scan
64-slice : USD 40
128-slice: USD 40
128-slice: USD 200
X-ray scan USD 3 USD 10
Ultrasound USD 3 USD 10
Average wait time Both MRI & CT scans 2-3 weeks About 4 hours to a day
Average age of device All Devices
60% > 5 years old
40% < 5 years old
70% > 5 years old
30% < 5 years old
“Compared to developed countries, cost of
diagnostic imaging services in Myanmar is still
affordable. A major barrier to the upgrade of
equipment is patient’s limited spending power
as new and advanced machines will increase
prices.
Source: MOH, Solidiance Interviews and Analysis

In-vitro
Diagnostics
(IVD) in
Myanmar:
market
challenges

Private facilities are leading
IVD testing in Myanmar
60%
20%
16%
3% 1%
Private Laboratories
Private Hospitals
Public Hospitals
Foreign branches
Public Laboratories
Diagnostic centers
In Myanmar, 2015
~ 200 (Total)
• Nearly all private laboratories are
standalone with 40% market share
in medical check-ups and laboratory
testing services
• There are only two standalone
public laboratories, each in Yangon &
Mandalay
• A limited number of large private
hospitals have their own laboratories
providing services ranging from basic
medical check-up to specific intensive
testing
More than half of the population in the
three major cities in Myanmar are from
middle-income class, hence large private
hospitals and standalone laboratories are
concentrated in these cities only. A few
foreign hospitals have testing centers in
Yangon, however, these are only for patients
that are referred by a parent hospital in the
originating country.
Due to high outbound medical tourism to
Thailand, Bangkok Hospital & Bumrungrad
International Hospital have set up testing
centers in Yangon to cater to after-care
needs of their patients.

Myanmar is facing population pressure
with increasing proportion of people
above 60 years old.
Growing usage of modern IVD is
essential to reduce cost and increase
operational efficiency for the healthcare
facilities.
Furthermore, sedentary lifestyle,
unhealthy eating habits and lack
of regular check-up has led to high
prevalence of diabetes, hypertension
and cervical cancer.
7.0%
7.4%
7.8%
8.2%
8.6%
9.0%
9.4%
9.8%
10.2%
10.6%
13.8%
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
16.0%
2013 2014 2015f 2016f 2017f 2018f 2019f 2020f 2021f 2022f 2030f
Increased penetration of IVD in Myanmar is due
to growing aging population and high prevalence of
major diseases
Percentage of Myanmar’s population >60 years old
Diabetes prevalence
rate
Hypertension
prevalence rate
Cervical cancer
incidence rate
• 6% nationwide
• 12% in rural population
• Over 1 million are
undiagnosed
• 23.8% nationwide
• Nearly 3.5 million are
undiagnosed
• 2.5% in Myanmar
while Southeast Asia’s
average is 1.7%, mainly
due to lack of early
diagnosis

The number of laboratories in Myanmar
has increased in the last 3 years, but it is still
insufficient to meet growing demand
Key laboratories offering IVD tests in Myanmar
Hospitals
Standalone local
laboratories
Foreign
laboratories
Key distributors in Myanmar’s
medical devices industry
The majority of the tests are performed in the standalone
local labs due to the affordability and the perceived accuracy
of the test results. Doctors usually refer outpatients to have
the specialty tests performed at standalone clinics.
On the other hand, foreign labs have been entering Myanmar
since 2010.
DKSH is the leading distributor for pharmaceutical products
and medical devices in Myanmar. DKSH has been in Myanmar
for over 15 years - currently distributing brands like Roche &
Novartis.
Sealion is also a key distributor and has had partnerships with
GE healthcare, Johnson & Johnson, Festo, 3M and Medtronic.
Mega Lifesciences entered Myanmar in 1995. The rest of
other local medical devices distributors include Myanmar
Zircon, Okkar Thiri and Medi Power.

Some key IVD tests in Myanmar
IVD Tests Sub-Category Test Private Public
Molecular Diagnostic
• Quantitative tests (HBV,
HCV, HIV, HPV)
• USD 100-150 (per test) • USD 0-20 (per test)
Biochemistry
• Liver profile
• Renal profile
• Lipid profile
• Protein test
• Cardiac profile
• Diabetes Test
• Other tests
• USD 20 – 40 (for basic
profiling tests)
• USD 50 - 120 (for
screening package)
• USD 0-15
• No screening package
Immunology
• Quantitative test
• Screening test
• Hormones
• Tumor markers
• Rheumatology
• USD 10 – 30 (for
antibody tests such as
HBV, HIV, Malaria and
etc.)
• USD 0-7 (for specific
tests for antibody)
Haematology
• Coagulation screening
• Iron study
• USD 7 (basic Rh Check-
blood protein test)
• USD 0-1.5 (basic RH
check)
Microbiology
• Culture & Sensitivity
• Routine examination
• USD 5 (Urine (RE) test)
• USD 0-1 (Urine (RE)
test)
Histopathology
• Cytology (Fluid, Sputum)
• Tissue biopsy
• USD 10-12 (Biopsy test;
each tissue sample from
1-3 cm)
• USD 0-1 (Urine (RE)
test)

Though majority of the IVD tests are done in Myanmar,
people still opt to do tests abroad for specific diseases for
better accuracy
Most of the basic IVD tests are done in Myanmar. However, to ensure accuracy,
upper middle class (which represents ~10% of the population) get their IVD tests
for specific diseases such as detailed tissue biopsy, tumor marker and C1 esterase
inhibitor in Thailand and Singapore.
Doctor, SSC Hospital
“In Myanmar, there is little spending on IVD
due to limited awareness ofthe usage and its
benefits. However, with increasing outreach
of media and health education programs,
IVD will see significant growth in the next 3-5
years.

of total healthcare budget is used for IVD in Myanmar
of total healthcare budget is used for IVD in ASEAN-5*
Director, Private Laboratory
“
<1%
2% - 3%
Biochemistry tests are the majority
of IVD tests done in Myanmar
with its basic screening packages
such as liver, renal, cardiac,
and diabetes profiling tests.
Microbiology and Immunology
are closely linked and often
difficult to distinguish. These 2
combined are one-third of the
total tests. Molecular diagnostic is
a very small market and we need
to increase its penetration.
IVD budget allocation in Myanmar in 2014
Percentage split of IVD tests done in
Myanmar in 2014
40%
20%
15%
10%
10%
5%
Biochemisry
Immunology
Microbiology
Hematology
Molecular Diagnostics
Histopathology
*ASEAN 5 includes Indonesia, Malaysia, Philippines, Thailand, and Vietnam

Registration & licensing of
Diagnostic Imaging (DI) and In-vitro
diagnostic (IVD) equipment
Compared with complex and long registration of pharmaceutical products, registration for imaging devices and medical
equipment is quite simple and normally takes 2-3 months
• All in-vitro-diagnostics equipment is required to apply for quality check and
license from FDA.
• Medical imaging devices like X-rays, MRI and CT scanners are exempted
from FDA license as no formal medical devices law has been passed yet
• Timeline is up to 3 months
• Medical Association MPMEEA (Myanmar Pharmaceutical and Medical
Equipment Entrepreneurs Association) has the price and control check on
newly applied medical imaging devices and IVDs. it works with ministries
of health and commerce for recommendation
• Timeline is up to 1-2 weeks
• After quality and price check of new products, MPMEEA sends
recommendation to Department of Trade to register products with Ministry
of Commerce with required documents such as test manual, country of
origin and COA (certificate of evaluation analysis)
• Timeline is up to 1-2 weeks
Source: Food and Drug Administration, Ministry of Commerce, MPMEEA, Solidiance Research & Analysis
FDA:
Approval
License
MPMEEA:
Price Control
Check
Dept. of Trade:
Registration

Case studies

Asia Royal
HospitalAsia Royal Hospital is a leading private hospital in the heart of Yangon city
Some IVD devices at Asia Royal Hospital
• Cobas e411
• Sysmex (XT 2001, CA-50, XT
2000i)
• Pentra 60+
• Liza (300 Plus, 300 Hyel)
• Vitros ECI
• Minividasi
• Partec SL3
• VITEK2 Compact 30
• BACT/ALERT 3D 60
• Cyflow Counter-Partec
• Easylite Plus / Plus (Na/K/
CL Analyser)
• Haemocue Hb200 (+) /
Albumin 201
• SYSXT-4000i
• Mini Vidas
• Urometer 120
• C311
• Option 2+
Established :
2000 (One of the first
private hospitals in
Myanmar)
Occupancy Rate :
>90% (2013) for 232
beds
Outpatient rate : ~250,000 (per year)
Inpatient rate : ~11,000 (per year)
DI & IVD Services : Available
33%
25%
18%
11%
9%
4% USA
Japan
France
Germany
China
Sweden
IVD - Installed base in Asia Royal Hospital by
country of origin (as of Aug 2015)
Doctor, Asia Royal Hospital
“Mostofthetests conducted in private hospital laboratories are
basic tests for medical screening packages in biochemistry.
But speciality tests such as immunology and biopsy are mostly
referred to private laboratories.
Source: Asia Royal Hospital, Solidiance Interviews & Analysis

Diagnostic Imaging Devices - Installed base in Asia Royal
Hospital by country of origin (as of Aug 2015)
Types of DI device Model of devices
X-ray
• 630 mA Shimazu
• 550 mA Siemens
• 330 mA Siemens
Portable X-ray 250 mA
C-Arm X-Ray Siremobile Siemens
CT Scanner
Somatom Sensation 64 Slice
Emotion DUO
ECG
Cardiofax 6511
Schiller AT1/CH 6340
Schiller AT1
Cardiofax 96 20L
Echo Scanner
Echo Cardiogram (S-2000)
Acuson X 300
Cypress
USSH 140a
Ultrasound
4D Ultrasound (X-300)
G 20
EUB405B
33%
25%
18%
11%
Germany
U.S.A
Switzerland
Japan

Yangon
General
Hospital
(YGH)
• YGH is a major public hospital, providing 24 specialized treatments
and is the best teaching hospital in Myanmar
• Yangon General Hospital is one of the five public hospitals equipped
with MRI scanners
• Fewer number of CT & MRI machines is causing long waiting time and
results are also delayed by up to 2 weeks.
• In early 2014, YGH installed new equipment from Varian Medical
Systems and procured new medical linear accelerator technology for
high-dose-rate brachytherapy for cancer treatment
Hospitals providing Radiation Therapy in
Myanmar (as of 2015)
Yangon General Hospital (Yangon) Public
Mandalay General Hospital (Mandalay) Public
Sao San Htun Hospital (Taungyi) Public
Nay Pyi Taw Hospital. (Nay Pyi Taw) Public
Pin Lon Hospital (Yangon) Private
• 1,500 beds
• 24 specialized departments
• Emergency care for general medicine, general surgery and
traumatology
• Staff: Approximately 300 doctors and over 400 nurses
• Teaching hospitals of University of Medicine 1, Yangon Institute
of Nursing and University of Paramedical Science
• 123 staff in Radiology Department
Yangon general hospital

key
takeaways
Shifts in Myanmar’s healthcare system are
creating emerging opportunities for private
healthcare companies across the country, but
it requires them to have a long term strategic
view of the market.
Major demographic changes and fast income
growth have affected a significant increase
in demand for Diagnostic Imaging & In-Vitro
Diagnostics. However, market still requires
efforts in increasing awareness about non-
communicable diseases and effects of
specialized testing.
Pricing is a key challenge that needs immediate
attention especially in the private sector. Local
hospitals, clinics & laboratories need assistance
from global healthcare companies in devising a
value proposition that would be appealing to
the patients.
Myanmar patients spent ~USD 210 million
in 2014 on outbound medical tourism. This
is a large patient base that can be tapped in
Myanmar to meet their diagnostics needs.

$$ $$
$$
has the lowest
healthcare
spending in
Southeast Asia.
total healthcare
expenditure
Take up 14% of total
hospitals
50% of private hospitals
have <25 beds
Only available in public tertiary
hospitals & big private hospitals
but IVD tests for some speciﬁc diseases are done abroad for accuracy
are leading the IVD market
Diagnostic Imaging (DI)
In-vitro Diagnostics
Demands are rising for :
of Myanmar’s population
reside in rural areas with
minimal access to
healthcare services
Death by
non-communicable
diseases (NCD)
Drivers of IVD
penetration
increase
Most IVD tests are done in Myanmar
2,7%
70%
40%
7%
in 2014 on outbound medical
tourism
Only
to cross
of GDP in 2014
for 2015 - 2016
(2010 - 2014)
share
Patients spent
$$ ~ USD 210 million
Myanmar
Myanmar's
USD 2 billion
Private hospitals
Take up ~86% of total
hospitals
Quality is far behind
regional standards
Due to non-detection in
early stages
Suggesting need for
better diagnostic services
Growing aging
population
High prevalence
of major diseases
(diabetes,
hypertension,
cervical cancer)
Public hospitals
Private facilities
Myanmar hospitals
Myanmar
is a large patient
base for healthcare
$
$
$ $$
PASSPORTMyanmar's
Healthcare
overview
HOSPITAL
increasedby
Advanced
diagnostics
Myanmar's
Diagnostic
Imaging
MARKET
Myanmar's
IN-VITRO
Diagnostic
MARKET
Source: Solidiance, www.solidiance.com

Authors
Omar Aziz | Associate Partner
Omar Aziz is an Associate Partner at Solidiance. Equipped with over 9 years of experience
in consulting, he has managed large projects in pharmaceutical, healthcare devices
& healthcare infrastructure domain. His expertise are in helping multinational clients
understand the Asian market landscape by profiling industries and competition, sizing the
markets, segmenting customers, analyzing distribution channels, preparing investment
feasibility studies, identifying suppliers, reviewing potential joint ventures or acquisitions,
and delivering market entry and growth strategy in Asia. Omar speaks regularly at
healthcare conferences, most recently, he conducted a workshop on ‘Myanmar Hospital
Build’ at ‘2nd Healthcare Facilities Asia 2015’.
Shin Thant Aung | Analyst
Shin Thant is an Analyst based in Solidiance’s Yangon office in Myanmar. He is a part
of Solidiance’s healthcare practice and has worked on a number of key projects. He
understands the distribution scenario & regulatory frameworks for healthcare products and
maintains good relations with key distributors and government agencies. Prior to joining
Soildiance, he had been working as an advisory associate in a top four global accounting
and consulting firm. Shin holds a Bachelor of Science degree in applied accounting from
Oxford Brookes University.
Mie Ko | Analyst
Mie Ko is an Analyst based in Solidiance’s Yangon office in Myanmar. Mie Ko worked on
several projects for Solidiance in Myanmar where she supported feasibility studies and
investment projects for Fortune 500 companies. Prior to joining our team, she worked at
the Finance Department of a large hospitality group in Yangon. Mie Ko holds an MBA with
specialization in Strategic International Marketing from the Asian Institute of Technology.

What We Do
Soldiance is a corporate strategy consulting firm with focus
on Asia Pacific. We advise CEOs on make-or-break deals,
define new business models and accelerate Asia growth.
Through our 10 offices across Asia, we provide our clients
with a better understanding of intrinsic regional issues. To
learn more about how Solidiance has helped many Fortune
500 & Asian Conglomerates to succeed in Asia, please visit:
http://www.solidiance.com/clients.
What We Are Focusing On
Our industry experience is centered on healthcare, industrial
applications, clean technology, and technology. Our Asian
market entry and growth strategy services provide the
required insights and the necessary roadmap to capture a
profitable market share in the region.
Additional Details
Solidiance has offices in China, India, Indonesia, Malaysia,
Myanmar, Philippines, Singapore, Thailand, UAE and
Vietnam. We are fast expanding and always on the lookout
for exceptional people.
About
Us

solidiance
China
Suite 2101, Hong Kong
Plaza, No 283 Middle
Huaihai Road,
Shanghai 200021
Phone: +86 21 5113 2131
Indonesia
Oleos I Building
6th FLoor - Unit 612
Jl. Mampang Prapatan Raya
No. 139A, Jakarta 12950
Phone : +62 21 7918 0330
Myanmar
4th Floor, Shwe Gon Plaza
Kabar Aye Pagoda Road
Bahan Township, Yangon
Myanmar - 11201
Phone: +95 979 700 6465
Singapore
Suite 07-05
High Street Centre, 1 North
Bridge Road
Singapore 179094
Phone: + 65 31520301
UAE
Suite 402D - Dark Green
Building, TwoFour54
Sheikh Zayed Road
Opposite Khalifa Park
Abu Dhabi, United Arab
Emirates
PO Box 769338
Phone: +971 (0) 24 420 420
India
Suite M-38/1 3/Floor,
IBC Tower. Middle Circle,
Connaught Place,
New Delhi – 110001
Phone: +91 11 4152 7888
Malaysia
23A-02 Binjai 8 Premium
SOHO, 8 Lorong Binjai
Kuala Lumpur 50450
Phone: +60 3 21 810 692
Philippines
Unit 2105, Tycoon Centre
Pearl Drive, Ortigas Centre
Pasig City, Metro Manila
Phone: +63 2531 8346
Thailand
Interchange Tower 21
#2109 - 21F
399 Sukhumvit Road
North Klongtoey, Wattana
Bangkok 10110
Phone: +66 26112664
Vietnam
Suite 704,
Satra Dong Khoi Building
58 Dong Khoi street
District 1, Ho Chi Minh City
Phone: +84 835218639
Website:
http://www.solidiance.com
Email:
info@solidiance.com
Our
Offices

Emerging Opportunities in Myanmar's Diagnostic Imaging and In-Vitro Diagnostics

Recommended

Recommended

More Related Content

Similar to Emerging Opportunities in Myanmar's Diagnostic Imaging and In-Vitro Diagnostics

Similar to Emerging Opportunities in Myanmar's Diagnostic Imaging and In-Vitro Diagnostics (20)

More from Solidiance

More from Solidiance (20)

Recently uploaded

Recently uploaded (20)

Emerging Opportunities in Myanmar's Diagnostic Imaging and In-Vitro Diagnostics